Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Health-related quality of life with encorafenib plus binimetinib for BRAF V600E thyroid cancer.

European thyroid journal - 1 Apr 2026

Kiyota Naomi, Tahara Makoto, Imai Hiroo, Takahashi Shunji, Nishiyama Akihiro, Tamura Shingo, Shimizu Yasushi, Kadowaki Shigenori, Ito Ken-Ichi, Hirashima Yoshinori, Ueno Shinji, Sugitani Iwao

Abstract excerpt

Background: A Japanese phase 2 trial of encorafenib plus binimetinib met the primary endpoint of the centrally assessed objective response rate in patients with unresectable BRAF V600E-mutated thyroid cancer. Consequently, encorafenib plus binimetinib has been approved in Japan. We present the health-related quality of life (HR-QoL) outcomes from the trial. Methods: The multicenter, open-label, uncontrolled phase...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Benzimidazoles

Share to Carbamates

Share to Proto-Oncogene Proteins B-raf

Share to Quality of Life

Share to Sulfonamides

Share to Thyroid Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 41885282
DOI: 10.1530/ETJ-25-0273
PMCID: PMC13052824

Genes

BRAF

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Health-related quality of life with encorafenib plus binimetinib for BRAF V600E thyroid cancer.PMID 41885282Read ↗

A Phase 2 Study of Encorafenib in Combination with Binimetinib in Patients with Metastatic BRAF-Mutated Thyroid Cancer in Japan.Semantic proximity Read ↗

Phase II, Open-Label Study of Encorafenib Plus Binimetinib in Patients With BRAFV600-Mutant Metastatic Non-Small-Cell Lung Cancer.Semantic proximity Read ↗

Quality of life with encorafenib plus cetuximab with or without binimetinib treatment in patients with BRAF V600E-mutant metastatic colorectal cancer: patient-reported outcomes from BEACON CRC.Semantic proximity Read ↗

Quality of life in patients with BRAF-mutant melanoma receiving the combination encorafenib plus binimetinib: Results from a multicentre, open-label, randomised, phase III study (COLUMBUS).Semantic proximity Read ↗

Outcome of initial lenvatinib treatment in patients with unresectable anaplastic thyroid cancerSemantic proximity Read ↗

Safety and Efficacy of Encorafenib, Binimetinib, and Cetuximab for BRAFV600E-Mutant Metastatic Colorectal Cancer: Results of the Japanese Expanded Access Program.Semantic proximity Read ↗

Encorafenib and binimetinib followed by radiotherapy for patients with BRAFV600-mutant melanoma and brain metastases (E-BRAIN/GEM1802 phase II study).Semantic proximity Read ↗

Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial.Semantic proximity Read ↗

Intracranial antitumor efficacy of combination treatment with encorafenib plus binimetinib in BRAF V600E-mutated anaplastic thyroid carcinoma.Semantic proximity Read ↗

Evaluation of Quality of Life in Patients With Gastric Adenocarcinoma Receiving Chemoradiotherapy: a Cross-sectional StudySemantic proximity Read ↗

Current and Future Perspectives of Health-Related Quality of Life in Resectable EGFR-Mutated Non-Small Cell Lung Cancer: A Podcast.Semantic proximity Read ↗

Quality of life with gefitinib in patients with EGFR-mutated non-small cell lung cancer: quality of life analysis of North East Japan Study Group 002 Trial.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.